Table of Contents
Chromatography Research International
Volume 2014, Article ID 307430, 5 pages
http://dx.doi.org/10.1155/2014/307430
Research Article

Method Development and Validation for Determination of Febuxostat from Spiked Human Plasma Using RP-HPLC with UV Detection

School of Pharmaceutical Sciences, Jaipur National University, Jaipur-Agra Bypass, Near New RTO Office, Jagatpura, Jaipur, Rajasthan 302017, India

Received 18 July 2014; Accepted 12 November 2014; Published 27 November 2014

Academic Editor: Susana Casal

Copyright © 2014 Monita Gide et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Evans, A Handbook of Bioanalysis and Drug Metabolism, edited by G. Evans, CRC Press, Boca Raton, Fla, USA, 2004.
  2. A. R. Buick, M. V. Doig, S. C. Jeal, G. S. Land, and R. D. McDowall, “Method validation in the bioanalytical laboratory,” Journal of Pharmaceutical and Biomedical Analysis, vol. 8, pp. 629–637, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. L. R. Snyder, J. J. Kirkland, and J. L. Glajch, Practical HPLC Method Development, John Wiley and Sons, New York, NY, USA, 2nd edition, 1997.
  4. B. G. Smith, A Handbook of Bioanalysis and Drug Metabolism, CRC Press, Boca Raton, Fla, USA, 2004.
  5. S. G. Schulman and S. H. Curry, “Analysis of biologic fluids,” in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. C. Boylan, Eds., vol. 1, pp. 217–231, Marcel Dekker, New York, NY, USA, 1988. View at Google Scholar
  6. M. D. Mayer, R. Khosravan, L. Vernillet, J.-T. Wu, N. Joseph-Ridge, and D. J. Mulford, “Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment,” American Journal of Therapeutics, vol. 12, no. 1, pp. 22–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. V. R. R. Vaka, J. K. Inamadugu, N. R. Pilli, M. Ramesh, and H. R. Katreddi, “A sensitive LC-MS/MS method for the quantification of febuxostat in human plasma and its pharmacokinetic application,” Biomedical Chromatography, vol. 27, no. 11, pp. 1406–1412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Lukram, S. Parmar, and A. Hande, “Determination of febuxostat in human plasma using ultra-performance liquid chromatography tandem mass spectrometry,” Drug Testing and Analysis, vol. 5, no. 6, pp. 492–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Wang, P. Deng, X. Chen, L. Guo, and D. Zhong, “Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma,” Biomedical Chromatography, vol. 27, no. 1, pp. 34–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Zhang, Y. Sun, P. Zhang, J. Gao, S. Wang, and Z. He, “Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in dog plasma and its application to a pharmacokinetic study,” Biomedical Chromatography, vol. 27, no. 2, pp. 137–141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Ding, Q. Zhang, Z. Wang, and G. Lin, “Development and validation of liquid chromatography-mass spectrometry method for determination of febuxostat in rat plasma and its application,” Latin American Journal of Pharmacy, vol. 31, no. 2, pp. 321–325, 2012. View at Google Scholar · View at Scopus
  12. B. A. Grabowski, R. Khosravan, L. Vernillet, and D. J. Mulford, “Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects,” Journal of Clinical Pharmacology, vol. 51, no. 2, pp. 189–201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Khosravan, B. Grabowski, J.-T. Wu, N. Joseph-Ridge, and L. Vernillet, “Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects,” British Journal of Clinical Pharmacology, vol. 65, no. 3, pp. 355–363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Khosravan, M. J. Kukulka, J.-T. Wu, N. Joseph-Ridge, and L. Vernillet, “The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase,” The Journal of Clinical Pharmacology, vol. 48, no. 9, pp. 1014–1024, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Khosravan, B. A. Grabowski, M. D. Mayer, J.-T. Wu, N. Joseph-Ridge, and L. Vernillet, “The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase,” Journal of Clinical Pharmacology, vol. 46, no. 1, pp. 88–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. U. S. Department of Health and Human Services, Food, and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, U. S. Department of Health and Human Services, FDA, 2001.